14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NBP vs NGNE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, NBP (NBP) captures the overall head-to-head institutional edge over Neurogene, Inc. (NGNE) on higher Unified Composite conviction (51.9/100 HOLD vs. 38.8/100 SELL) after splitting the core matrix 4–3 (led by Valuation Multiples, Options & Positioning), while NGNE wins 3–2 across the 6-pillar growth and valuation breakdown. NBP trades at $0.79 (2.7x Forward P/E, 0.0% operating margin) versus NGNE at $23.42 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: NBP earns the overall head-to-head edge with a stronger Unified Composite Score (51.9/100 HOLD vs. NGNE 38.8/100 SELL) and 1.66β · 81% Vol risk profile, whereas NGNE leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: NBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.1); meanwhile NGNE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NBP vs NGNE. Trailing 12-month operating profitability (NBP 0.0% vs NGNE 0.0%) and valuation multiples (NBP 2.7x vs NGNE N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $494.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ NBP vs NGNE Key Questions & Quantitative Answers
As of Nov 16, 2026, NBP (NBP) captures the overall head-to-head institutional edge over Neurogene, Inc. (NGNE) on higher Unified Composite conviction (51.9/100 HOLD vs. 38.8/100 SELL) after splitting the core matrix 4–3 (led by Valuation Multiples, Options & Positioning), while NGNE wins 3–2 across the 6-pillar growth and valuation breakdown. NBP trades at $0.79 (2.7x Forward P/E, 0.0% operating margin) versus NGNE at $23.42 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: NBP earns the overall head-to-head edge with a stronger Unified Composite Score (51.9/100 HOLD vs. NGNE 38.8/100 SELL) and 1.66β · 81% Vol risk profile, whereas NGNE leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.1); meanwhile NGNE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NGNE leads the Growth & Scale pillar: NBP posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NGNE at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NBP generates N/A in USD-normalized revenue versus N/A for NGNE. In operating R&D and SG&A reinvestment, NBP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NGNE.
NBP screens cheaper on headline valuation multiples. NBP trades at 2.7x Forward P/E, 2.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NGNE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NBP (-59.1% ROE) versus NGNE (-38.4% ROE) capital efficiency.
In options market volatility and institutional positioning, NBP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.66β · 81% Vol realized risk). By comparison, NGNE carries 97.1% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.55β · 89% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.